Evidence map›Paper›PMID 38726410›Full record

ReviewFood science & nutrition2024

Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.

Hafiza Madiha Jaffar, Fahad Al-Asmari, Faima Atta Khan, Muhammad Abdul Rahim, Eliasse Zongo

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. International journal of molecular sciences · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hafiza Madiha JaffarUniversity Institute of Diet & Nutritional Sciences, Faculty of Allied Health Sciences The University of Lahore Lahore Pakistan.
Fahad Al-AsmariDepartment of Food and Nutrition Sciences, College of Agricultural and Food Sciences King Faisal University Al-Ahsa Saudi Arabia.ORCID https://orcid.org/0000-0003-4253-2796
Faima Atta KhanUniversity Institute of Diet & Nutritional Sciences, Faculty of Allied Health Sciences The University of Lahore Lahore Pakistan.
Muhammad Abdul RahimDepartment of Food Science, Faculty of Life Sciences Government College University Faisalabad Pakistan.
Eliasse ZongoLaboratoire de Recherche et d'Enseignement en Santé et Biotechnologies Animales Université Nazi BONI Bobo Dioulasso Burkina Faso.ORCID https://orcid.org/0000-0001-9885-8301

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver diseases, encompassing conditions such as cirrhosis, present a substantial global health challenge with diverse etiologies, including viral infections, alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). The exploration of natural compounds as therapeutic agents has gained traction, notably the herbal remedy milk thistle (

Indexed as

fatty liver diseasemilk thistlenon‐alcoholic fatty liver diseasesilibininsilymarin

Identifiers

PMID38726410
PMCPMC11077231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.